READ-ONLY DIGITIZATION RESULT
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.
J Immunother Cancer · 2024-Nov-27 · PMID 39608979
Panel A提取完成待 EXE 对齐验证
OS
Figure 3. Clinical outcomes in patients who completed 2 years of camrelizumab. ( A ) Kaplan-Meier estimates for OS. ( B ) Kaplan-Meier estimates for PFS. ( C ) Kaplan-Meier estimates for DoR. Tumor responses were assessed by investigator per RECIST version 1.1. Camre+chemo, camrelizumab plus chemotherapy; DoR, duration of response; OS, overall survival; PFS, progression-free survival.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
| Curve | 序号 | X (norm) | Y (norm) | X (real) | Y (real) | X (pixel) | Y (pixel) |
|---|---|---|---|---|---|---|---|
| 1 | 1 | 0.0000 | 0.0913 | 0.0000 | 9.1255 | 104 | 270 |
| 1 | 2 | 0.0479 | 0.0913 | 3.4512 | 9.1255 | 133 | 270 |
| 1 | 3 | 0.0496 | 0.0913 | 3.5702 | 9.1255 | 134 | 270 |
| 1 | 4 | 0.0512 | 0.0837 | 3.6893 | 8.3650 | 135 | 272 |
| 1 | 5 | 0.0529 | 0.0837 | 3.8083 | 8.3650 | 136 | 272 |
| 1 | 6 | 0.0545 | 0.0837 | 3.9273 | 8.3650 | 137 | 272 |
| 1 | 7 | 0.0562 | 0.0837 | 4.0463 | 8.3650 | 138 | 272 |
| 1 | 8 | 0.0579 | 0.0837 | 4.1653 | 8.3650 | 139 | 272 |
| 1 | 9 | 0.0595 | 0.0837 | 4.2843 | 8.3650 | 140 | 272 |
| 1 | 10 | 0.0612 | 0.0837 | 4.4033 | 8.3650 | 141 | 272 |
| 1 | 11 | 0.0628 | 0.0837 | 4.5223 | 8.3650 | 142 | 272 |
| 1 | 12 | 0.0645 | 0.0875 | 4.6413 | 8.7452 | 143 | 271 |
| 1 | 13 | 0.0661 | 0.0875 | 4.7603 | 8.7452 | 144 | 271 |
| 1 | 14 | 0.0678 | 0.0875 | 4.8793 | 8.7452 | 145 | 271 |
| 1 | 15 | 0.0694 | 0.0875 | 4.9983 | 8.7452 | 146 | 271 |
| 1 | 16 | 0.0711 | 0.0875 | 5.1174 | 8.7452 | 147 | 271 |
| 1 | 17 | 0.0727 | 0.0875 | 5.2364 | 8.7452 | 148 | 271 |
| 1 | 18 | 0.0744 | 0.0798 | 5.3554 | 7.9848 | 149 | 273 |
| 1 | 19 | 0.0760 | 0.0798 | 5.4744 | 7.9848 | 150 | 273 |
| 1 | 20 | 0.0777 | 0.0798 | 5.5934 | 7.9848 | 151 | 273 |
| 1 | 21 | 0.0793 | 0.0798 | 5.7124 | 7.9848 | 152 | 273 |
| 1 | 22 | 0.0810 | 0.0798 | 5.8314 | 7.9848 | 153 | 273 |
| 1 | 23 | 0.0826 | 0.0798 | 5.9504 | 7.9848 | 154 | 273 |
| 1 | 24 | 0.0843 | 0.0798 | 6.0694 | 7.9848 | 155 | 273 |
| 1 | 25 | 0.0860 | 0.0798 | 6.1884 | 7.9848 | 156 | 273 |
| 1 | 26 | 0.0876 | 0.0798 | 6.3074 | 7.9848 | 157 | 273 |
| 1 | 27 | 0.0893 | 0.0798 | 6.4264 | 7.9848 | 158 | 273 |
| 1 | 28 | 0.0909 | 0.0951 | 6.5455 | 9.5057 | 159 | 269 |
| 1 | 29 | 0.0926 | 0.0951 | 6.6645 | 9.5057 | 160 | 269 |
| 1 | 30 | 0.0942 | 0.0951 | 6.7835 | 9.5057 | 161 | 269 |
| 1 | 31 | 0.0959 | 0.0798 | 6.9025 | 7.9848 | 162 | 273 |
| 1 | 32 | 0.0975 | 0.0798 | 7.0215 | 7.9848 | 163 | 273 |
| 1 | 33 | 0.0992 | 0.0798 | 7.1405 | 7.9848 | 164 | 273 |
| 1 | 34 | 0.1008 | 0.0798 | 7.2595 | 7.9848 | 165 | 273 |
| 1 | 35 | 0.1025 | 0.0798 | 7.3785 | 7.9848 | 166 | 273 |
| 1 | 36 | 0.1041 | 0.0798 | 7.4975 | 7.9848 | 167 | 273 |
| 1 | 37 | 0.1058 | 0.0798 | 7.6165 | 7.9848 | 168 | 273 |
| 1 | 38 | 0.1074 | 0.0798 | 7.7355 | 7.9848 | 169 | 273 |
| 1 | 39 | 0.1091 | 0.0798 | 7.8545 | 7.9848 | 170 | 273 |
| 1 | 40 | 0.1107 | 0.0798 | 7.9736 | 7.9848 | 171 | 273 |
| 1 | 41 | 0.1124 | 0.0798 | 8.0926 | 7.9848 | 172 | 273 |
| 1 | 42 | 0.1140 | 0.0837 | 8.2116 | 8.3650 | 173 | 272 |
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 1 | 2026-07-23T18:36:05+00:00 |